DDInter1042 DDInter419
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical".. This low affinity to dopamine receptors results in fewer extrapyramidal side effects, especially tardive dyskinesia. However, its promiscuity toward the muscarinic and adrenergic receptors can result in other side effects, notably gastrointestinal hypomotility and orthostatic hypotension. [L905,A215552]. Despite its effectiveness in treating both positive and negative symptoms of schizophrenia, clozapine was briefly removed from the market in various jurisdictions in 1970 due to severe agranulocytosis.[A256713,A256718] However, continued evidence of its effectiveness led to clozapine's eventual reintroduction, although with a reluctance to prescribe it. Clozapine was approved by the FDA in 1989 for treatment-resistant schizophrenia under the brand CLOZARIL. Due to its severe adverse effects profile, clozapine is only available through a restricted program under a Risk Evaluation Mitigation Strategy (REMS) called the Clozapine REMS Program.
Clozapine {u} (Compound) resembles {v} (Compound) Trifluoperazine
Clozapine {u} (Compound) resembles {v} (Compound) Prochlorperazine
Clozapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Azatadine
Clozapine {u} (Compound) binds {v} (Gene) CYP2D6
Clozapine {u} (Compound) upregulates {v} (Gene) ST3GAL5
Clozapine {u} (Compound) palliates {v} (Disease) bipolar disorder
Clozapine {u} (Compound) downregulates {v} (Gene) POLR2I
Clozapine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Clozapine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Caffeine
Clozapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Trospium
Clozapine (Compound) resembles Trifluoperazine (Compound)
Clozapine (Compound) resembles Prochlorperazine (Compound)
Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Azatadine
Clozapine (Compound) binds CYP2D6 (Gene)
Clozapine (Compound) upregulates ST3GAL5 (Gene)
Clozapine (Compound) palliates bipolar disorder (Disease)
Clozapine (Compound) downregulates POLR2I (Gene)
Clozapine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Clozapine may cause a minor interaction that can limit clinical effects when taken with Caffeine
Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Trospium